-transparent.png){kind=logo}
•Genomic tumor testing is an important tool in guiding treatment for gynecologic malignancies.•Targetable mutations may lead to new therapies in gynecologic cancer treatment.•Her2/neu mutations in serous ovarian carcinomas can be targeted with ERBB2 inhibitors.•Afatinib shows promising response rates in lung cancers carrying Her2/neu mutations.•Afatinib may be effective in serous ovarian tumors exhibiting Her2/neu or ERBB2 mutations.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
August 2005,
The Australian & New Zealand journal of obstetrics & gynaecology,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
June 1987,
Gynecologic oncology,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
April 2022,
World journal of clinical cases,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
November 2003,
Zhonghua fu chan ke za zhi,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
July 1999,
Gynecologic oncology,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
November 1987,
Zhonghua fu chan ke za zhi,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
October 1994,
Gynecologic oncology,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
September 2007,
Gynecologic oncology,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
January 1999,
Zhonghua fu chan ke za zhi,
Amanda L Shepherd-Littlejohn, and
Wyatt J Hanft, and
Vanessa A Kennedy, and
Edwin A Alvarez
August 2005,
Gynecologic oncology,
